17 May 2023 in Meditsinskiy sovet = Medical Council
The prevalence of GERD in most European countries and the Russian Federation is at the level of 15–20%. Hydrochloric acid plays a significant and sometimes major role in damage to the mucosa of the upper gastrointestinal tract (GIT) in patients with various acid-related diseases. Despite the presence of various classes of drugs that reduce the damaging effect of hydro-chloric acid on the mucous membrane of the upper gastrointestinal tract, acid-related diseases continues to be an urgent medical problem. The review article discusses the issues of pharmacological treatment of acid-related diseases. Such classes of drugs as antacids, H2-histamine blockers, gastroprotectors, potassium-competitive blockers of hydrochloric acid secretion are described in detail. Particular attention is paid to the group of proton pump inhibitors (PPIs). The paper evaluates the merits of each class of drugs, their significance in the treatment of acid-related diseases. One of the most popular PPIs in the Russian Federation is omeprazole. The effectiveness of the drug is determined by pharmacokinetic parameters, in particular bioavailability. The bioavailability of omeprazole of various trade names varies widely. To increase the rate and completeness of dissolution, and hence the bioavailability of poorly soluble molecules in the modern pharmaceutical industry, various disintegrants are used as excipients. The addition of sodium superdisintegrant carboxymethyl starch to the new Omez® dosage form with MiniCaps technology promotes an accelerated and more complete intake of omeprazole into the systemic circulation, helping to increase bioavailability. In addition, the innovative dosage form has a volume that is 30% smaller than the classic capsule, which improves ease of use and adherence to treatment.
1 November 2022 in Medical alphabet
This literature review is devoted to the problem of epilepsy caused by pituitary neuroendocrine tumors: their detailed classification with the latest recommendations of the World Health Organization 2022, clinical picture of each variant of pituitary neuroendocrine tumor in a complex multidisciplinary approach are considered. The main feature of the review is a detailed consideration of the epilepsy associated with this condition, which is considered to be a rather rare manifestation of the disease (incidence in patients is 0.5 %), due to which very few cases of epilepsy in patients with pituitary adenoma have been described in the literature. Our work has analyzed the fundamental works of domestic scientists in this field, as well as current information from foreign sources and most of the available clinical cases of epilepsy in this group of patients, revealing in detail the pathogenesis of epilepsy at all levels, including molecular changes. Modern techniques for the treatment approach in this group of patients are also described, the effectiveness of drug and surgical therapy is analyzed according to the criteria of the frequency of long-term persistent remission and recurrence, side effects of drugs and complications of transsphenoidal tumor resection are reviewed, including in terms of possible epilepsy; conclusions about the most rational and effective approach to treatment of various types of hypophysial neuroendocrine tumors are drawn.
3 July 2024 in HERALD of North-Western State Medical University named after I.I. Mechnikov
МВМирцхулава Вахтанг Вахтангович
Мирцхулава Вахтанг Вахтангович
+3
BACKGROUND: Micronutrient deficiencies, including deficiencies of vitamins and microelements, are a major public health concern worldwide. They are highly prevalent, particularly in developing countries, and have significant health consequences, including anemia, impaired immune function, cognitive impairment, and growth retardation. Micronutrient deficiencies can also contribute to the development of chronic diseases, such as cardiovascular disease and diabetes. Micronutrient deficiencies can also contribute to the development of chronic diseases. AIM: To study the knowledge, interest and motivation of different population groups regarding vitamin and micronutrient intake. MATERIALS AND METHODS: The original questionnaire with 45 questions was completed by 344 respondents: 141 (41%) without medical education, 91 (25.4%) with higher medical education, 112 (32.6%) by students of medical unvesities. RESULTS: Only 100 (29.4%) respondents considered their nutrition balanced. 180 (52.3%) people did not consume vegetables and fruits on a daily basis, 82 (23.3%) respondents almost never consumed fish and seafood. Almost all respondents [335 (97.4%)] took some vitamin and mineral complex at least in one of the periods of their life, 284 (82.6%) — did it without a doctor’s prescription. Female respondents demonstrated a higher level of knowledge about the problem under study: 115 (41.9%) women and only 17 (24.2%) men had checked vitamin D levels (p = 0.006), while 187 (68.2%) women and only 33 (47.1%) men had taken vitamin D (p = 0.006). Those receiving/having higher medical education were more likely to take vitamin D (4.4 times), vitamin B6 (3.8 times), selenium (3 times), and zinc (2.8 times) than non-medical respondents. CONCLUSIONS: The nature of nutrition indicates potential risks of micronutrient imbalance in the respondents. Knowledge about the problem of micronutrient imbalances among the study participants is not systematized. Men and people without medical education have less knowledge on this topic and are less likely to take various micronutrients.
24 June 2025 in Modern Rheumatology Journal
The potential link between targeted therapies and malignancies (MN) in patients with inflammatory joint diseases and a history of MNs remains a frequent concern in routine rheumatological practice.In 2024, the EULAR (European Alliance of Associations for Rheumatology) task force formulated five overarching principles and seven hypotheses regarding the initiation of targeted therapy in patients with active arthritis and MN in remission, as well as one hypothesis for patients with active arthritis who have not achieved remission of the oncological disease.Key considerations included: a) the necessity of assessing the individual risk of cancer recurrence based on patient-specific factors, the type of MN, and the underlying disease; b) the importance of close cooperation with oncology specialists and determining the therapeutic strategy through shared decision-making between the patient and rheumatologist; c) the need for the timely initiation of appropriate targeted arthritis therapy in patients with cancer remission; d) a recommendation to use Janus kinase inhibitors and abatacept cautiously and only when no alternatives are available, due to the lack of data on their use in patients with prior MN.These guidelines identify specific points that require particular attention when prescribing targeted therapy to patients with active arthritis and a history of MN.